Aditxt, Inc. (NASDAQ: ADTX)

Aditxt, Inc. is a biotechnology company focused on developing immune modulation technologies and diagnostic platforms to address autoimmune diseases cancer and infectious diseases. Headquartered in Mountain View California the company was incorporated in Delaware in September 2017 and pursues a mission of decentralizing health innovation through stakeholder engagement. Its core activities include research and development of proprietary therapeutic candidates advancement of biomarker discovery programs and preparation of clinical trial materials.

Aditxt, Inc. generates revenue primarily through licensing of its proprietary technologies to partners and collaborators. The company has entered into license agreements with Loma Linda University for its apoptotic DNA immunotherapy platform and with Stanford University for immune response detection technologies. It also grants sublicenses such as the non exclusive license for SARS CoV 2 antibody testing to a CLIA CAP certified laboratory and seeks future revenue from commercialization of its product candidates after regulatory approval.

The company operates through the following segments:

• Adimune focuses on immune modulation therapeutic programs using its apoptotic DNA immunotherapy platform to induce tolerance in autoimmune diseases and transplant rejection. The lead candidate ADI 100 targets glutamic acid decarboxylase for potential treatment of type 1 diabetes psoriasis and central nervous system disorders. Pre clinical studies have demonstrated durable tolerance induction without impairing infection fighting capacity and have supported manufacturing of clinical grade drug substance for upcoming trials. Adimune has engaged contract research organizations and is preparing for clinical studies in psoriasis and type 1 diabetes with plans to evaluate stiff person syndrome in collaboration with the Mayo Clinic.

• Pearsanta develops mitochondrial DNA based biomarkers for early detection of cancer and other diseases through its Mitomic technology platform. The company acquired the Mitomic assets from MDNA Life Sciences and operates a high complexity CLIA CAP accredited laboratory in Richmond Virginia to support assay development. Current product candidates include a blood based test for prostate cancer and a test for endometriosis while ongoing work seeks to identify biomarkers for ovarian lung pancreatic liver breast stomach esophageal and colorectal cancers.

• Adivir is dedicated to advancing antiviral and antimicrobial solutions to address unmet needs in infectious disease and population health. The subsidiary focuses on identifying developing and commercializing therapeutic candidates for life threatening viral infections and emerging pathogens. Its strategy includes leveraging both novel and repurposed approaches to improve treatment access in underserved regions.

• Adifem pursues women's health initiatives aiming to create innovative therapies for conditions with significant unmet medical need. Although the proposed acquisition of Evofem Biosciences was not completed the subsidiary continues to explore opportunities in contraception hormonal regulation and related therapeutic areas. Its efforts align with Aditxt's broader goal of expanding into underserved therapeutic sectors.

Aditxt, Inc. occupies a niche in the biotechnology sector where it combines immune tolerance induction with mitochondrial DNA based diagnostics to differentiate from conventional immunosuppression and broad spectrum antibody assays. Competitors in the immune tolerance space include companies pursuing antigen specific regulatory T cell therapies and cytokine blockers while in the diagnostic arena firms offering liquid biopsy and polygenic risk scores represent alternatives. The company's competitive advantages stem from its mechanism that mimics natural apoptosis to achieve antigen specific tolerance without global immune suppression and from its proprietary platforms that enable high sensitivity multiplexed detection of immune responses and mitochondrial DNA alterations.

Aditxt, Inc. serves patients physicians and research institutions through its therapeutic and diagnostic programs. Specific collaborators mentioned in the filing include the Mayo Clinic for clinical trial execution Loma Linda University and Stanford University for technology licensing and a CLIA CAP certified laboratory in Richmond Virginia that performs SARS CoV 2 antibody testing under a non exclusive agreement.